Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (7250)	12/4/1999 7:56:00 PM
From: Vector1	Respond to of 9719

Good point, 14 patients, however, my guess is we will get a continued update flow at conferences on the others in the trial. Still 14 out of 14 is quite good and 71% complete responses is downright exciting. If a majority of the complete responses can be confirmed at the molecular level then we may really have something exciting. It looks like the battle lines are Rit plus CHOP vs Bex plus Fludara in first line and Bex v Zev for refactory. Hopefully athe biggest winners will be the patients. V1